Malawi Becomes Fourth African Nation to Approve Lenacapavir, Gilead's Twice-Yearly HIV Prevention Injectable
Key Insights
Malawi's Pharmacy and Medicines Regulatory Authority approved lenacapavir following a 46-day expedited review, making it the fourth African nation to authorize the injectable HIV (search) prevention drug.
The drug, developed by Gilead Sciences Ireland (search), is administered through a single injection every six months and represents a major breakthrough in HIV (search) prevention for a country with 950,000 people living with the disease.
Health experts describe the approval as transformative for preventive outcomes, as the twice-yearly injection significantly reduces the burden of adherence and clinic visits compared to daily oral medications.
Malawi's Pharmacy and Medicines Regulatory Authority (PMRA) has approved lenacapavir, an injectable HIV (search) prevention drug developed by Gilead Sciences Ireland (search), following a 46-day expedited review. The approval makes Malawi the fourth African nation to authorize the medicine, joining South Africa, Zambia, and Zimbabwe in pioneering access to this innovative prevention strategy.
The drug represents a significant advancement in HIV (search) prevention, administered through a single injection every six months rather than requiring daily oral medication. This dosing schedule addresses critical adherence challenges that have historically limited the effectiveness of HIV prevention programs.
Regulatory Breakthrough in High-Burden Setting
Dr. Beatrice Matanje, executive director of Malawi's National AIDS Commission (search) (NAC), described the approval as a "great milestone" in the country's fight against HIV (search). "This approval represents a major breakthrough in the prevention of HIV. We are actually motivated to fight on as a commission to reduce the rate of infection among Malawians," Matanje told Anadolu.
The approval comes at a critical time for Malawi, which continues to battle some of the world's highest HIV (search) prevalence rates. According to the National AIDS Commission (search), approximately 950,000 Malawians are living with HIV, with women and children comprising the majority of cases.
Transformative Impact on Prevention Outcomes
The twice-yearly injection schedule offers substantial advantages over existing prevention methods. "A twice-yearly injection significantly reduces the burden of adherence and clinic visits, and this has the potential to transform preventive outcomes," Matanje explained.
PMRA's Director General Mphatso Kawaye characterized the approval as part of a "deliberate strategy to accelerate access to life-saving innovations." He emphasized that "this expedited regulation of lenacapavir showcases PMRA's unwavering commitment to fast-tracking high-quality, safe, and effective medicines for Malawians."
International Collaboration Accelerates Access
The approval was facilitated through joint collaboration with the European Medicines Agency (search) (EMA) and the World Health Organization (WHO), which has been instrumental in accelerating regulatory decisions across Southern Africa. This collaborative approach has enabled Malawi to position itself among the world's earliest pioneers of the drug.
The Global Fund (search), an international financing and partnership organization, has committed to supporting Malawi's adoption of lenacapavir. According to recent statements from the organization, first consignments are expected to arrive in Africa by the end of the year, marking a crucial step toward implementation of this prevention strategy in high-burden settings.